Literature DB >> 27911301

Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease.

Andrea Slachevsky1,2,3,4, Leonardo Guzmán-Martínez5, Carolina Delgado6, Pablo Reyes1, Gonzalo A Farías5,6, Carlos Muñoz-Neira2, Eduardo Bravo7, Mauricio Farías7, Patricia Flores2,8, Cristian Garrido6, James T Becker9,10,11, Oscar L López9,10, Ricardo B Maccioni5,12.   

Abstract

BACKGROUND: Intracellular neurofibrillary tangles are part of the core pathology of Alzheimer's disease (AD), which are mainly composed of hyperphosphorylated tau protein.
OBJECTIVES: The purpose of this study is to determine whether high molecular weight (HMW) or low molecular weight (LMW) tau protein levels, as well as the ratio HMW/LMW, present in platelets correlates with brain magnetic resonance imaging (MRI) structural changes in normal and cognitively impaired subjects.
METHODS: We examined 53 AD patients and 37 cognitively normal subjects recruited from two Memory Clinics at the Universidad de Chile. Tau levels in platelets were determined by immunoreactivity and the MRI scans were analyzed using voxel-based morphometry in 41 AD patients.
RESULTS: The HMW/LMW tau ratio was statistically different between controls and AD patients, and no associations were noted between HMW or LMW tau and MRI structures. In a multivariate analysis controlled for age and education level, the HMW/LMW tau ratio was associated with reduced volume in the left medial and right anterior cingulate gyri, right cerebellum, right thalamus (pulvinar), left frontal cortex, and right parahippocampal region.
CONCLUSIONS: This exploratory study showed that HMW/LMW tau ratio is significantly higher in AD patients than control subjects, and that it is associated with specific brain regions atrophy. Determination of peripheral markers of AD pathology can help understanding the pathophysiology of neurodegeneration in AD.

Entities:  

Keywords:  Alzheimer’s disease; medial temporal lobe atrophy; non-invasive biomarkers; tau variants

Mesh:

Substances:

Year:  2017        PMID: 27911301     DOI: 10.3233/JAD-160652

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

Review 1.  Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers.

Authors:  Michelle M Mielke
Journal:  J Appl Lab Med       Date:  2020-01-01

2.  Platelet Function Is Associated With Dementia Risk in the Framingham Heart Study.

Authors:  Jaime Ramos-Cejudo; Andrew D Johnson; Alexa Beiser; Sudha Seshadri; Joel Salinas; Jeffrey S Berger; Nathanael R Fillmore; Nhan Do; Chunlei Zheng; Zanetta Kovbasyuk; Babak A Ardekani; Nunzio Pomara; Omonigho M Bubu; Ankit Parekh; Antonio Convit; Rebecca A Betensky; Thomas M Wisniewski; Ricardo S Osorio
Journal:  J Am Heart Assoc       Date:  2022-04-26       Impact factor: 6.106

3.  Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease.

Authors:  Silvia Fossati; Jaime Ramos Cejudo; Ludovic Debure; Elizabeth Pirraglia; Je Yeong Sone; Yi Li; Jingyun Chen; Tracy Butler; Henrik Zetterberg; Kaj Blennow; Mony J de Leon
Journal:  Alzheimers Dement (Amst)       Date:  2019-06-28

Review 4.  Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease.

Authors:  Lenka Hromadkova; Saak Victor Ovsepian
Journal:  J Immunol Res       Date:  2019-08-06       Impact factor: 4.818

Review 5.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.